Stoke Therapeutics (STOK) EBT Margin (2022 - 2026)
Stoke Therapeutics (STOK) recorded quarterly EBT Margin of 802.75% in Q1 2026, up 80.54% quarter-over-quarter from 4124.39% in Q4 2025, and down 87474.0% on a YoY basis from N/an in Q1 2025.
Stoke Therapeutics (STOK) EBT Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 802.75% for Q1 2026.
- In Q1 2026, EBT Margin fell 87474.0% year-over-year to 802.75%; the TTM figure through Mar 2026 stood at 532.84% (down 55974.0% YoY), while the FY2025 annual figure was 3.71%, up 23904.0% from the prior year.
- EBT Margin was 802.75% for Q1 2026 at Stoke Therapeutics, up from 4124.39% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 71.99% in Q1 2025 to a low of 4124.39% in Q4 2025.
- Historically, EBT Margin has averaged 811.69% across 5 years, with a median of 743.14% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBT Margin surged 91632 bps in 2024, then slumped 407715 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 786.32% in 2022, then dropped by 23 bps to 963.56% in 2023, then surged by 95 bps to 47.24% in 2024, then sank by 8631 bps to 4124.39% in 2025, then soared by 81 bps to 802.75% in 2026.
- The last three EBT Margin figures came in at 802.75% (Q1 2026), 4124.39% (Q4 2025), and 372.7% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.95 Bn | - | -802.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -802.75% |
| Dec 31, 2025 | -4,124.39% |
| Sep 30, 2025 | -372.70% |
| Jun 30, 2025 | -169.96% |
| Mar 31, 2025 | 71.99% |
| Dec 31, 2024 | -47.24% |
| Sep 30, 2024 | -540.05% |
| Jun 30, 2024 | -531.88% |
| Mar 31, 2024 | -625.57% |
| Dec 31, 2023 | -963.56% |
| Sep 30, 2023 | -743.14% |
| Jun 30, 2023 | -1,237.20% |
| Mar 31, 2023 | -438.41% |
| Dec 31, 2022 | -786.32% |
| Sep 30, 2022 | -900.28% |
| Jun 30, 2022 | -764.28% |
| Mar 31, 2022 | -823.03% |